{
  "pmcid": "12304718",
  "sha256": "da10970791f3cca55938a827a33cd775fb3f52885f6c864a96db3f85e66da0b8",
  "timestamp_utc": "2025-11-09T15:36:17.184184+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.492049752249976,
    "reading_ease": 26.44428152492671,
    "word_count": 341
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This double-blinded randomized-controlled trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This double-blinded randomized-controlled trial included 50 patients undergoing primary THA in 2021–2023."
      },
      "Participants": {
        "score": 2,
        "evidence": "50 patients undergoing primary THA in 2021–2023."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received TXA intravenously. The placebo group received 0.9% sodium chloride solution."
      },
      "Objective": {
        "score": 1,
        "evidence": "We hypothesized that no difference exists in the degree of fibrinolysis and blood loss between patients receiving prophylactic TXA and placebo."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome measure was to quantitate the degree of fibrinolysis measured by maximum lysis (ML) demonstrated by ROTEM variables."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 2,
        "evidence": "This double-blinded randomized-controlled trial"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "This double-blinded randomized-controlled trial included 50 patients undergoing primary THA in 2021–2023."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Blood coagulability tested by ROTEM was within the normal range in all patients, and no difference was found between the TXA group and placebo group."
      },
      "Harms": {
        "score": 1,
        "evidence": "no patient developed fibrinolysis during the entire perioperative phases."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Clinicaltrials.gov ( NCT03897621 )"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Department of Anesthesiology funding, 10.13039/100008513 Thomas Jefferson University Hospital ."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}